3-(3-Hydroxy-1-oxo-2-phenylpropo-xy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo(3.2. 1)octanbromid,(endo,syn)-(+-)-

Gefahreninformationscode (GHS)

• Bildanzeige (GHS)

  

• Alarmwort

  Warnung

• Gefahrenhinweise

  H302：Gesundheitsschädlich bei Verschlucken.

  H319：Verursacht schwere Augenreizung.

  H332：Gesundheitsschädlich bei Einatmen.

• Sicherheit

  P261：Einatmen von Staub vermeiden.

  P304+P340：BEI EINATMEN: Die Person an die frische Luft bringen und für ungehinderte Atmung sorgen.

  P305+P351+P338：BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen.

Ipratropium bromide Chemische Eigenschaften,Einsatz,Produktion Methoden

• R-Sätze Betriebsanweisung:

  R20/22:Gesundheitsschädlich beim Einatmen und Verschlucken.
  R36:Reizt die Augen.

• S-Sätze Betriebsanweisung:

  S26:Bei Berührung mit den Augen sofort gründlich mit Wasser abspülen und Arzt konsultieren.

• Chemische Eigenschaften

  White Powder

• Originator

  Atrovent,Boehringer Ingelheim,W. Germany,1975

• Verwenden

  Ipratropium Bromide is a nonselective muscarinic acetylcholine receptor antagonist; bronchodilator.

• Verwenden

  N-Isopropyl quaternary salt of Atropine. Nonselective muscarinic acetylcholine receptor antagonist; bronchodilator

• Verwenden

  This drug exhibits broncholytic action by reducing cholinergic influence on bronchial musculature (m-cholinoblocking action). It relieves bronchial spasms. It is used to treat and prevent minor and moderate bronchial asthma, especially asthma that is accompanied by cardiovascular system diseases.

• Definition

  ChEBI: The anhydrous form of the bromide salt of ipratropium. An anticholinergic drug, ipratropium bromide blocks the muscarinic cholinergic receptors in the smooth muscles of the bronchi in the lungs. This opens the bronchi, so providing relief in chronic obstru tive pulmonary disease and acute asthma.

• Manufacturing Process

  21 1.5 g (0.667 mol) of N-isopropyl-noratropine were dissolved at 60°C in 2.11 liters of absolute toluene in a 3-liter glass pressure tube. While the solution was still warm, 95 g (1 mol) of ice-cold methylbromide were added, and the pressure tube was sealed immediately thereafter. The reaction mixture was kept at 60°C for four days. After one hour of standing, the formation of crystals began. At the end of four days the crystals were separated by vacuum filtration at 60°C, washed with 600 cc of toluene at 60°C, and dried in vacuo in a drying cabinet at 100°C. Raw yield: 263.7 g (95.8% of theory). MP: 224°C to 225°C (decomp.). The raw product was refluxed with 2.5 liters of chloroform for 30 minutes, vacuum filtered whilehot, washed with 200 cc of chloroform, and dried in a vacuum drying cabinet at 100°C. Yield: 249 g (90.6% of theory). MP: 226°C to 228°C (decomp.). The purified product was recrystallized from 1.2 liters of n-propanol, washed with 200cc of n-propanol and dried in a vacuum drying cabinet at 100°C. Yield: 237 g (86.15% of theory). MP: 230°C to 232°C (decomp.). By evaporation of the mother liquor to 100 cc another 6.0 g of the pure product, MP 230°C to 231.5°C (decomp.), were obtained.

• Trademarks

  Atrovent (Boehringer Ingelheim).

• Therapeutic Function

  Bronchodilator

• Allgemeine Beschreibung

  Ipratropium bromide, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo[3.2.1]octane bromide (Atrovent), is a quaternaryammonium derivative of atropine. It is freely soluble inwater and ethanol but insoluble in chloroform and ether. Thesalt is stable in neutral and acidic solutions but rapidly hydrolyzedin alkaline solutions.

• Biologische Aktivität

  Muscarinic antagonist, bronchodilator. N-Isopropyl salt of atropine.

• Clinical Use

  Ipratropium bromide (Atrovent) is a quaternary amine derivative that is used via inhalation in the treatment of chronic obstructive pulmonary disease and to a lesser extent, asthma.

• Clinical Use

  Ipratropium bromide is used in inhalation therapy toproduce dilation of bronchial smooth muscle for acute asthmaticattacks. The drug produces bronchodilation by competitiveinhibition of cholinergic receptors bound to smooth muscle of the bronchioles. Ipratropium may also act on thesurface of mast cells to inhibit ACh-enhanced release ofchemical mediators. The drug has a slow onset of action,within 5 to 15 minutes after being administered by inhalation,and should not be used alone for acute asthmatic attacks.The peak therapeutic effect from one dose is observedbetween 1 and 2 hours. The effects of the drug last for about6 hours. It has a half-life of 3.5 hours.

• Synthese

  Ipratropium bromide, 3|á-hydroxy-8-isopropyl-1|áH,5|áH-tropanium bromide (23.3.6), is synthesized by reacting N-isopropylnoratropine with methyl bromide.

  

• Veterinary Drugs and Treatments

  Locally administered (inhaled) ipratropium bromide can be used for the adjunctive treatment of bronchospastic conditions.

Ipratropium bromide Upstream-Materialien And Downstream Produkte

3-(3-Hydroxy-1-oxo-2-phenylpropo-xy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo(3.2. 1)octanbromid,(endo,syn)-(+-)- Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(256)Suppliers

22254-24-6, Ipratropium bromide Verwandte Suche: